Entheogenix Biosciences Inc. has described 5-HT2A receptor agonists reported to be useful for the treatment of post-traumatic stress, depression and anxiety disorders.
Sensorium Therapeutics Inc. has identified alkylated derivatives of mesembrine or mesembrenone acting as serotonin transporter (SERT) and/or phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of anxiety, depression and stress disorders.
Tetra Pharm Technologies ApS and Kvanctify ApS have entered into a strategic partnership to accelerate the identification and development of novel drug candidates targeting the endocannabinoid system.
Finding an effective medication for patients with major depressive disorder is notoriously difficult, with 70% of patients failing to respond to the first drug prescribed and 30% not responding to the first four medications. Complicating matters, genetic mutations can increase psychotropic drug-related adverse events, including hospitalizations. A recent study indicates Myriad Genetics Inc.’s Genesight test can help minimize the risk of these negative events, with a reduction of nearly 40% in psychiatric-related hospitalizations and prescription of medications with significant gene-drug interactions.
Addex Therapeutics has offloaded its portfolio of preclinical allosteric modulation drugs into Neurosterix, a new company that arrives on the scene with a $63 million series A round.
Cannabinoid CB2 receptor and serotonin 5-HT1A receptor agonists have emerged as therapeutic options for their antidepressive and anxiolytic properties, apart from being linked to synergistic antinociceptive activity when used in combination in animal tests.
In a first, the U.S. FDA accepted an artificial intelligence (AI)/machine learning-model into its Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program for drug development. The program will support use of Deliberate AI Inc.’s anxiety and depression assessment tool, called the AI-generated Clinical Outcome Assessment, as a qualified drug development tool.
In a first, the U.S. FDA accepted an artificial intelligence (AI)/machine learning-model into its Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program for drug development. The program will support use of Deliberate AI Inc.’s anxiety and depression assessment tool, called the AI-generated Clinical Outcome Assessment (AI-COA), as a qualified drug development tool.
After flying high in 2022, digital therapeutics (DTx) companies crashed to Earth in 2023 and scrambled to identify a path to profitability, or at least continued viability.